Global and United States Artificial Blood Market Report & Forecast 2022-2028

Artificial blood, also called oxygen therapeutics or hemoglobin-based oxygen carriers, offer the promise of new life-saving medical treatments.
Market Analysis and Insights: Global and United States Artificial Blood Market
This report focuses on global and United States Artificial Blood market, also covers the segmentation data of other regions in regional level and county level.
Due to the COVID-19 pandemic, the global Artificial Blood market size is estimated to be worth US$ 3505 million in 2022 and is forecast to a readjusted size of US$ 6771.3 million by 2028 with a CAGR of 11.6% during the review period. Fully considering the economic change by this health crisis, by Type, Human Blood accounting for % of the Artificial Blood global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR in the post-COVID-19 period. While by Application, Hemoglobin-Based Oxygen Carriers (HBOCs) was the leading segment, accounting for over percent market share in 2021, and altered to an % CAGR throughout this forecast period.
Artificial blood or synthetic blood and blood products are the alternatives to the blood transfusion to replace the blood. It fulfills and replicates the normal functions of the body. Artificial blood is infused in the traumatic injuries and other disease conditions for the transportation of carbon di oxide and oxygen across the body.
Global Artificial Blood Scope and Market Size
Artificial Blood market is segmented by region (country), players, by Type and by Application. Players, stakeholders, and other participants in the global Artificial Blood market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application for the period 2017-2028.
For United States market, this report focuses on the Artificial Blood market size by players, by Type and by Application, for the period 2017-2028. The key players include the global and local players, which play important roles in United States.
Segment by Type
Human Blood
Synthetic Blood
Animal Blood
Segment by Application
Hemoglobin-Based Oxygen Carriers (HBOCs)
Perflurocarbon Emulsions (PFCEs)
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
By Company
Dextro-Sang Corporation
BioPure Corporation
Sangart
Northfield Laboratories
Baxter International
Dentritech
FluorO2 Therapeutics
Nuvox Pharma
Alpha Therapeutic Corporation
HemoBioTech